Page 2 - David Hung News Today

NUV-1511 is the first clinical candidate from the company’s novel drug-drug conjugate platform Company anticipates initiating a Phase 1/2 clinical study of NUV-1511 in 1H 2024 ...

The season of giving is in full swing. Here's a guide to the best types of items to donate for toy drives, and what and who are usually forgotten.

NEW YORK--(BUSINESS WIRE)--Nov 13, 2023--

Phase 1 monotherapy study of NUV-868 and Phase 1b study of NUV-868 in combination with olaparib or enzalutamide are ongoing Expect to submit an IND for first Drug-Drug Conjugate clinical candidate...

02.11.2023 - Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the third quarter ended ...

MARKHAM, Ontario, Oct. 04, 2023 -- Sienna Senior Living Inc. announced that it will report its 2023 third quarter results after market close on Thursday, November 9, 2023. Nitin Jain, President...

MARKHAM, Ontario, June 30, 2023 -- Sienna Senior Living Inc. announced that it will report its 2023 second quarter results after market close on Thursday, August 10, 2023. Nitin Jain, President...

This past week in healthcare investigations

Scientific Advisory Board members bring significant global expertise in oncology drug and clinical development ... | June 1, 2023

MARKHAM, Ontario, April 04, 2023 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) announced that it will report its...